11/19
12:52 pm
indv
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Low
Report
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
11/7
02:24 pm
indv
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Medium
Report
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
10/30
12:30 pm
indv
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
Low
Report
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
10/25
11:26 am
indv
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $15.00.
Low
Report
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $15.00.
10/24
02:05 pm
indv
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
10/24
02:00 am
indv
Indivior Announces Q3 2024 Financial Results
Low
Report
Indivior Announces Q3 2024 Financial Results
10/24
02:00 am
indv
Indivior Announces Q3 2024 Financial Results
Low
Report
Indivior Announces Q3 2024 Financial Results
10/13
10:01 am
indv
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 [Seeking Alpha]
Medium
Report
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 [Seeking Alpha]
10/11
11:24 am
indv
Indivior PLC (NASDAQ: INDV) had its price target lowered by analysts at Craig Hallum from $20.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Indivior PLC (NASDAQ: INDV) had its price target lowered by analysts at Craig Hallum from $20.00 to $16.00. They now have a "buy" rating on the stock.
10/11
10:35 am
indv
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock, down previously from $22.00.
Low
Report
Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock, down previously from $22.00.
10/10
07:00 am
indv
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
Medium
Report
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
10/10
07:00 am
indv
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
Medium
Report
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
10/7
11:30 am
indv
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
Low
Report
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review